Three-shot combo? Pfizer, BioNTech roll COVID-19 booster trial as real world data back first vaccine

Feb 25, 2021 11:55am
Pfizer and BioNTech dive into a third-dose Comirnaty vaccine trial, while a study out of Israel marks its initial success. (Getty/Meyer & Meyer)
As Pfizer and BioNTech start testing whether a third dose of their COVID-19 shot can help fend off new coronavirus variants, a massive real-world study has confirmed that its first, two-dose regimen is 94% effective.
The third-dose study now underway will gauge the effects of that follow-up dose on circulating and new COVID-19 virus variants.
At the same time, the companies are in talks with the FDA and EMA about studying a new booster specifically designed to tackle new variants. They're hoping to validate "future modified mRNA vaccines with a regulatory pathway similar to what is currently in place for flu vaccines,” according to a press release.

Related Keywords

Boston ,Massachusetts ,United States ,South Africa ,Israel ,Harvard University ,South African ,Albert Bourla ,Janet Woodcock ,Ugur Sahin ,Pfizer ,Clalit Research Institute In Tel Aviv ,New England Journal ,Clalit Research Institute ,Tel Aviv ,Boston Children ,போஸ்டன் ,மாசசூசெட்ஸ் ,ஒன்றுபட்டது மாநிலங்களில் ,இஸ்ரேல் ,ஹார்வர்ட் பல்கலைக்கழகம் ,ஜேனட் மரக்கட்டை ,ஃபைசர் ,புதியது இங்கிலாந்து இதழ் ,தொலைபேசி அவிவ் ,போஸ்டன் குழந்தைகள் ,